Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Maria Chiara Petrone

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1045-209X; OpenAlex author ID A5024532466. Sources: OpenAlex.

Their work

Papers
27 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 6 papers · 2022: 3 papers · 2023: 5 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 27

  1. Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. Co-author DOI 10.1002/ueg2.70179↗
  2. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  3. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
  4. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  5. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  6. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  7. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. First author DOI 10.1002/deo2.152↗
  8. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples. Co-author DOI 10.1016/j.cgh.2022.10.014↗
  9. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  10. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  11. Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15143704↗
  12. Needle-Tract Seeding of Pancreatic Cancer after EUS-FNA: A Systematic Review of Case Reports and Discussion of Management. Co-author DOI 10.3390/cancers14246130↗
  13. Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study. Co-author DOI 10.4103/eus-d-21-00111↗
  14. EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case-control stud… First author DOI 10.4103/eus-d-21-00200↗
  15. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  16. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  17. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  18. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  19. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  20. Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomi… First author DOI 10.3390/cancers13184512↗
  21. Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. Co-author DOI 10.1055/a-1221-9879↗
  22. RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. Co-author DOI 10.3390/cells9122561↗
  23. Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic canc… Co-author DOI 10.4103/eus.eus_16_19↗
  24. New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer. Co-author DOI 10.4251/wjgo.v11.i11.933↗
  25. The resectable pancreatic ductal adenocarcinoma: To FNA or not to FNA? A diagnostic dilemma, FNA pros. Co-author DOI 10.4103/eus.eus_64_17↗
  26. New strategies for the early detection of pancreatic cancer. Co-author DOI 10.1586/17474124.2016.1122521↗
  27. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Co-author DOI 10.1016/j.gie.2012.08.006↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paolo Giorgio Arcidiacono · 15 shared papers, 2012–2026 · strength 1.93
  2. Massimo Falconi · 12 shared papers, 2019–2026 · strength 1.72
  3. Gabriele Capurso · 11 shared papers, 2019–2026 · strength 1.57
  4. Michele Reni · 11 shared papers, 2012–2026 · strength 1.42
  5. Lívia Archibugi · 8 shared papers, 2017–2026 · strength 1.18
  6. Gemma Rossi · 8 shared papers, 2020–2026 · strength 1.15
  7. Claudio Doglioni · 7 shared papers, 2019–2023 · strength 0.91
  8. Sabrina Gloria Giulia Testoni · 7 shared papers, 2019–2023 · strength 0.81
  9. Emanuel Della‐Torre · 5 shared papers, 2020–2023 · strength 0.64
  10. Francesco DE COBELLI · 5 shared papers, 2020–2023 · strength 0.62
  11. Ruggero Ponz de Leon Pisani · 3 shared papers, 2022–2026 · strength 0.60
  12. Gianpaolo Balzano · 5 shared papers, 2012–2023 · strength 0.58
  13. Matteo Tacelli · 3 shared papers, 2022–2025 · strength 0.48
  14. Miriam Redegalli · 3 shared papers, 2019–2023 · strength 0.34
  15. Marina Macchini · 2 shared papers, 2023–2025 · strength 0.32
  16. Giulia Orsi · 2 shared papers, 2023–2025 · strength 0.32
  17. Giuseppe Vanella · 2 shared papers, 2023–2025 · strength 0.32
  18. Marco Schiavo Lena · 2 shared papers, 2023 · strength 0.28
  19. Giovanni Guarneri · 1 shared paper, 2025 · strength 0.18
  20. Domenico Tamburrino · 1 shared paper, 2025 · strength 0.18
  21. Gaetano Lauri · 1 shared paper, 2025 · strength 0.18
  22. Maria Pia Protti · 1 shared paper, 2023 · strength 0.14
  23. Claudia Minici · 1 shared paper, 2023 · strength 0.14
  24. Lucia B. De Monte · 1 shared paper, 2023 · strength 0.14
  25. Maria Giulia Cangi · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.